Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

Rekha Pal, Sara A. Monaghan, Andrea Cortese Hassett, Markus Y. Mapara, Peter Schafer, G. David Roodman, Margaret V. Ragni, Lynn Moscinski, Alan List, Suzanne Lentzsch

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with multiple myeloma, but the use of IMiDs in multiple myeloma is associated with neutropenia and increased risk for venous thromboembolism (VTE) by mechanisms that are unknown. We show that IMiDs down-regulate PU.1, a key transcription factor involved in granulocyte differentiation in vitro and in patients treated with lenalidomide. Loss of PU.1 results in transient maturation arrest with medullary accumulation of immature myeloid precursors and subsequent neutropenia. Accumulation of promyelocytes leads to high levels of the platelet aggregation agonist, cathepsin G stored in the azurophilic granules of promyelocytes. High levels of cathepsin G subsequently may increase the risk of VTE. To our knowledge, this is the first report investigating the underlying mechanism of IMiD-induced neutropenia and increased risk of VTE in multiple myeloma.

Original languageEnglish (US)
Pages (from-to)605-614
Number of pages10
JournalBlood
Volume115
Issue number3
DOIs
StatePublished - Jan 21 2010

Fingerprint

Venous Thromboembolism
Neutropenia
Multiple Myeloma
Cathepsin G
Granulocyte Precursor Cells
Down-Regulation
Derivatives
Platelets
Platelet Aggregation
Granulocytes
Transcription Factors
Agglomeration
Pharmaceutical Preparations
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Pal, R., Monaghan, S. A., Hassett, A. C., Mapara, M. Y., Schafer, P., Roodman, G. D., ... Lentzsch, S. (2010). Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood, 115(3), 605-614. https://doi.org/10.1182/blood-2009-05-221077

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. / Pal, Rekha; Monaghan, Sara A.; Hassett, Andrea Cortese; Mapara, Markus Y.; Schafer, Peter; Roodman, G. David; Ragni, Margaret V.; Moscinski, Lynn; List, Alan; Lentzsch, Suzanne.

In: Blood, Vol. 115, No. 3, 21.01.2010, p. 605-614.

Research output: Contribution to journalArticle

Pal, R, Monaghan, SA, Hassett, AC, Mapara, MY, Schafer, P, Roodman, GD, Ragni, MV, Moscinski, L, List, A & Lentzsch, S 2010, 'Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia', Blood, vol. 115, no. 3, pp. 605-614. https://doi.org/10.1182/blood-2009-05-221077
Pal, Rekha ; Monaghan, Sara A. ; Hassett, Andrea Cortese ; Mapara, Markus Y. ; Schafer, Peter ; Roodman, G. David ; Ragni, Margaret V. ; Moscinski, Lynn ; List, Alan ; Lentzsch, Suzanne. / Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. In: Blood. 2010 ; Vol. 115, No. 3. pp. 605-614.
@article{29300a3ed4f5457eafbd8bb5ca897407,
title = "Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia",
abstract = "The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with multiple myeloma, but the use of IMiDs in multiple myeloma is associated with neutropenia and increased risk for venous thromboembolism (VTE) by mechanisms that are unknown. We show that IMiDs down-regulate PU.1, a key transcription factor involved in granulocyte differentiation in vitro and in patients treated with lenalidomide. Loss of PU.1 results in transient maturation arrest with medullary accumulation of immature myeloid precursors and subsequent neutropenia. Accumulation of promyelocytes leads to high levels of the platelet aggregation agonist, cathepsin G stored in the azurophilic granules of promyelocytes. High levels of cathepsin G subsequently may increase the risk of VTE. To our knowledge, this is the first report investigating the underlying mechanism of IMiD-induced neutropenia and increased risk of VTE in multiple myeloma.",
author = "Rekha Pal and Monaghan, {Sara A.} and Hassett, {Andrea Cortese} and Mapara, {Markus Y.} and Peter Schafer and Roodman, {G. David} and Ragni, {Margaret V.} and Lynn Moscinski and Alan List and Suzanne Lentzsch",
year = "2010",
month = "1",
day = "21",
doi = "10.1182/blood-2009-05-221077",
language = "English (US)",
volume = "115",
pages = "605--614",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

AU - Pal, Rekha

AU - Monaghan, Sara A.

AU - Hassett, Andrea Cortese

AU - Mapara, Markus Y.

AU - Schafer, Peter

AU - Roodman, G. David

AU - Ragni, Margaret V.

AU - Moscinski, Lynn

AU - List, Alan

AU - Lentzsch, Suzanne

PY - 2010/1/21

Y1 - 2010/1/21

N2 - The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with multiple myeloma, but the use of IMiDs in multiple myeloma is associated with neutropenia and increased risk for venous thromboembolism (VTE) by mechanisms that are unknown. We show that IMiDs down-regulate PU.1, a key transcription factor involved in granulocyte differentiation in vitro and in patients treated with lenalidomide. Loss of PU.1 results in transient maturation arrest with medullary accumulation of immature myeloid precursors and subsequent neutropenia. Accumulation of promyelocytes leads to high levels of the platelet aggregation agonist, cathepsin G stored in the azurophilic granules of promyelocytes. High levels of cathepsin G subsequently may increase the risk of VTE. To our knowledge, this is the first report investigating the underlying mechanism of IMiD-induced neutropenia and increased risk of VTE in multiple myeloma.

AB - The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with multiple myeloma, but the use of IMiDs in multiple myeloma is associated with neutropenia and increased risk for venous thromboembolism (VTE) by mechanisms that are unknown. We show that IMiDs down-regulate PU.1, a key transcription factor involved in granulocyte differentiation in vitro and in patients treated with lenalidomide. Loss of PU.1 results in transient maturation arrest with medullary accumulation of immature myeloid precursors and subsequent neutropenia. Accumulation of promyelocytes leads to high levels of the platelet aggregation agonist, cathepsin G stored in the azurophilic granules of promyelocytes. High levels of cathepsin G subsequently may increase the risk of VTE. To our knowledge, this is the first report investigating the underlying mechanism of IMiD-induced neutropenia and increased risk of VTE in multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=77449111211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449111211&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-05-221077

DO - 10.1182/blood-2009-05-221077

M3 - Article

C2 - 19965623

AN - SCOPUS:77449111211

VL - 115

SP - 605

EP - 614

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -